
Multi-tenant SaaS pharmacovigilance and drug safety platform built on a cloud-native re-architecture of the legacy ARISg database, with end-to-end ICSR intake, MedDRA coding, E2B(R3) submission, aggregate reporting, and signal detection, plus an embedded GenAI/agentic AI layer (NavaX).
LifeSphere Safety comprises LifeSphere MultiVigilance (core case management), Advanced Intake (GenAI-powered case data extraction), Literature Intelligence, Field Safety Reporter (mobile data collection), Reporting & Analytics (LSRA), Advanced Signals, Advanced Compliance Docs (medical writing / PSMF management), and Clarity. NavaX is the cross-portfolio GenAI / agentic-AI engine that powers automation.
LifeSphere Safety is the modern, cloud-rebuilt successor to ArisGlobal's ARISg database (originally launched in the 1990s). ArisGlobal is headquartered in Miami, Florida. Nordic Capital Fund IX acquired the company in 2019 at a reported ~USD 700M valuation. By March 2022 the vendor reported 300+ Safety customers and 7M+ safety cases processed annually, with "4 of the 5 largest biopharmas" running LifeSphere Safety. In December 2019 ArisGlobal Services delivered what the vendor described as the industry's largest single PV implementation: a top-5 pharma go-live spanning 2,300+ end users, 6.8M migrated legacy cases, and >1M adverse-event cases per year.
The vendor states NavaX "supports customers and collectively processes 700,000 cases annually; that number is expected to expand to 2.5 million cases by mid-2026." In 2025 ArisGlobal received a Frost & Sullivan New Product Innovation Recognition for its agentic MedDRA Coding Agent. As of February 14, 2025 MultiVigilance also supports medical-device vigilance with EU MDR, IVDR, FDA, and PMDA device safety reporting.
Platform is pharma-and-biotech-native by design. As of February 14, 2025 MultiVigilance was extended to medical-device vigilance with explicit support for EU MDR, IVDR, and electronic submission to FDA and PMDA for device safety.
Multi-tenant SaaS, "the only unified, next-generation SaaS safety platform in production" per vendor. Third-party analysis identifies AWS as the hosting cloud provider with a quarterly release cadence. Specific data-residency regions, sovereign cloud options (EU, China, India, GovCloud), and tenant-isolation guarantees are not publicly enumerated. REST-API architecture with documented integration to EDC and CTMS systems for automatic SAE import, plus gateway connectors for EudraVigilance (EVWEB/AS2) and FDA ESG. Reference dictionaries integrated natively: MedDRA (including MedDRA J), WHO Drug Dictionary, NDC, EDQM, IMDRF. Recent Snowflake data partnership extends analytics. Single tenant supports both pharma and medical-device vigilance. SSO standards, mobile-app availability beyond Field Safety Reporter, browser-version matrix, and API rate limits are not publicly enumerated.
ArisGlobal does not publish list pricing. Third-party directories characterize the model as "subscription-based license… billed monthly or annually based on selected modules and user count… scalable for sponsors running multiple studies or expanding globally." Third-party analysis characterises enterprise / top-20 pharma deployments as "big-ticket systems (often tens of millions of dollars over years)". No published starting price; enterprise quote-only; trial availability not publicly enumerated. The April 2025 "Shared Success Model" reportedly ties a portion of fees to customer-realized automation ROI — contractual specifics not publicly enumerated.
ArisGlobal's largest publicly disclosed implementation — a top-5 pharma — went live in December 2019 with 2,300+ end users, migration of 6.8 million legacy cases, and an annual run-rate of more than 1 million adverse-event cases ("no critical issues" at go-live). In 2025, ArisGlobal reported 34 global go-lives and more than 100 new and expanded LifeSphere customers across the portfolio. Implementation is typically delivered by ArisGlobal's Services / Transformation Services team or by certified partners. The Ultragenic case study documents partner-led delivery with dedicated SMEs, multiple validation cycles for data migration, redefinition of distribution rules from regulatory manuals, and structured change-management support. Common third-party-flagged pitfalls: MedDRA recoding complexity when migrating from legacy systems, distribution-rule rebuild burden, change-management lift of moving 1,000+ users from on-prem ARISg or Argus to multi-tenant SaaS, and validation cycle depth for cases-in-flight migration. Vendor does not publish a deployment-timeline matrix by org size.
PharmaSpotter assessment from published vendor and third-party sources. No user reviews are on file for this product.
Users and third-party analysts consistently credit LifeSphere Safety on automation depth ("automation-first, multi-tenant architecture which promises major efficiency gains for global safety teams"), a pre-configured "out-of-the-box" deployment model that reduces custom development, and the breadth of the integrated PV portfolio (intake → coding → submission → analytics → signal) on one tenancy. Vendor-cited operating metrics most often credited: 80% case-processing efficiency gains versus legacy workflows, 65% faster case intake, 40-50% reduced false positives in Advanced Signals — vendor figures, not independently validated except for the 30% case-processing-time reduction independently CRO-validated in 2018.
The standardised configuration model reduces custom development but also reduces the granular workflow and user-role customisation some top-20 pharma operating models depend on. Third-party analysis characterises the automation model as vision-led: "Aris LifeSphere requires adapting to its vision of automated PV, which some organizations embrace and others find challenging." Public third-party review volume for LifeSphere Safety remains thin.
Share your experience with ArisGlobal LifeSphere Safety anonymously. Your insights help pharmaceutical professionals make better software decisions.
Contribute Anonymous FeedbackPublicly disclosed pharmaceutical and biotech organizations
Jump to section